S
Sapphiros
Consumer diagnostics company offering rapid, at-home tests for infectious diseases and personalized wellness insights
About Sapphiros
Sapphiros is a global AI Bio computational biology company that provides solutions to help people make informed decisions. They offer real-time, definitive results through their products, ranging from rapid home tests to advanced laboratory testing services. Sapphiros is a leader in genetic and COVID-19 testing, and are also developing a device that will provide the highest performing diagnostics in the palm of your hand. Additionally, they are creating a convenient patch for rapid, point of care diagnosis. They are also working on proprietary molecular detection technologies that will enable near patient and at-home testing for infectious diseases and generic indications. Sapphiros is backed by a team of experienced healthcare executives and a leading global investment firm, KKR. They are committed to investing in growth stage companies that have the vision and passion to bring transformative new diagnostic technologies to the world.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Boston, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 59.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Sapphiros.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jul 2026 | $12M | — | US Biomedical Advanced Research and Development Authority | ↗ |
| SERIES BOther financing | Jan 2024 | $30M | $120M | OraSure Technologies | ↗ |
Growth signals
Latest recorded traffic for Sapphiros is 3.3K monthly website visits, up 120% over the last three months. Sapphiros's team declined 30% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
US Biomedical Advanced Research and Development Authority
Series A2 investors entered at this stage
KKR
OraSure Technologies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sapphiros on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sapphiros’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.